Re: Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardio Benefits at Euro Society of Cardiology Congress 2024

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardio Benefits at Euro Society of Cardiology Congress 2024

in response to

Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardio Benefits at Euro Society of Cardiology Congress 2024

KOO-KOO2

posted on Sep 03, 2024 10:57AM

GOOGLE:

"Total GLP-1 users in the U.S. may number 30 mn by 2030 — or around 9% of the overall population."

"Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are second to third line antihyperglycaemic drugs commonly prescribed for the treatment of type 2 diabetes."